Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 92, Issue 4, Pages 467-475Publisher
WILEY
DOI: 10.1038/clpt.2012.120
Keywords
-
Categories
Funding
- National Institutes of Health/National Institute of General Medical Sciences Pharmacogenomics Research Network [U01 GM92666, U01 HL65899]
- American Lebanese Syrian Associated Charities
Ask authors/readers for more resources
Research on genes and medications has advanced our understanding of the genetic basis of individual drug responses. The aim of pharmacogenomics is to develop strategies for individualizing therapy for patients, in order to optimize outcome through knowledge of the variability of the human genome and its influence on drug response. Pharmacogenomics research is translational in nature and ranges from discovery of genotype-phenotype relationships to clinical trials that can provide proof of clinical impact. Advances in pharmacogenomics offer significant potential for subsequent clinical application in individual patients; however, the translation of pharmacogenomics research findings into clinical practice has been slow. Key components to successful clinical implementation of pharmacogenomics will include consistent interpretation of pharmacogenomics test results, availability of clinical guidelines for prescribing on the basis of test results, and knowledge-based decision support systems.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available